This study focuses on individuals who have a condition called HFpEF (heart failure with preserved ejection fraction). HFpEF occurs when the lower left chamber (left ventricle) is not able to fill properly with blood during the diastolic (filling) phase. The study will evaluate whether an investigational drug called mavacamten can lower blood levels of cardiac troponin (a marker of heart muscle injury) and/or NT-proBNP (a marker of heart wall stress), referred to as “cardiac biomarkers.” These cardiac biomarkers are increased in the blood of some people with heart failure with preserved ejection fraction (HFpEF). Additionally, the study will provide preliminary information regarding the tolerability and safety of mavacamten treatment in HFpEF. Given the open label design of the study, all enrolled patients will receive the study medication.
What is the full name of this clinical trial?
AN EXPLORATORY, OPEN-LABEL, PROOF-OF-CONCEPT, PHASE 2A STUDY OF MAVACAMTEN IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP